Fallon Wellness Pharmacy Recalls Papaverine Injection Due to Sterility Concerns
Fallon Wellness Pharmacy is recalling 8 vials of Papaverine/phentolamine/prostaglandin injection in New York due to a lack of assurance of sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The FDA classified this recall as Class II. According to the severity rubric, an FDA Class II recall is assigned a score of 4 (Severe), particularly when involving sterility issues in injectable medications which carry a risk of infection.
Plain-English summary
Fallon Wellness Pharmacy, L.L.C. is recalling 8 vials of Papaverine/phentolamine/prostaglandin 30/1/0.02 mg/mL Injection. The recall is limited to Lot # 11172014@75, which has an expiration date of 4/12/2015. The product was distributed in New York.
The recall was initiated because of a lack of assurance of sterility. The FDA has classified this recall as Class II, which indicates that use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Consumers who have this product should stop using it and contact their healthcare provider or the recalling firm for instructions on how to return or dispose of the medication.
The recalled product
- Product
- Papaverine/phentolamine/prostaglandin 30/1/0.02 mg/mL Injection, Fallon Wellness Pharmacy, L.L.C., Latham, NY 12110
- Manufacturer
- Fallon Wellness Pharmacy, L.L.C.
- Category
- Drug — Injectable Medication
- Affected units
- 8
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot #: a) 11172014@75- Exp 4/12/2015
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 10 recalled by Fallon Wellness Pharmacy, L.L.C. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 10 products in this recall →Related recalls
Same manufacturer · Fallon Wellness Pharmacy, L.L.C.
See all →- SevereFallon Wellness Pharmacy Recalls Papaverine Injection Due to Sterility Concerns
FDA (Drugs) · 2016-12-14
- SevereFallon Wellness Pharmacy Recalls PAPA/PHEN/PROST Injection Due to Sterility Concerns
FDA (Drugs) · 2016-12-14
- SevereFallon Wellness Pharmacy Recalls Papaverine Injection Due to Sterility Concerns
FDA (Drugs) · 2015-05-20
- SevereFallon Wellness Pharmacy Recalls Prostaglandin Rx Injections Due to Sterility Concerns
FDA (Drugs) · 2015-05-20
- SevereFallon Wellness Pharmacy Recalls Methylcobalamin/B-Complex Injection Due to Sterility Concerns
FDA (Drugs) · 2015-05-20
Same hazard · sterility
See all →- SevereK.C. Pharmaceuticals Recalls Target Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereFallon Wellness Pharmacy Recalls Papaverine Injection Due to Sterility Concerns
FDA (Drugs) · 2016-12-14
- SevereFallon Wellness Pharmacy Recalls PAPA/PHEN/PROST Injection Due to Sterility Concerns
FDA (Drugs) · 2016-12-14
- HighFDA Recalls Papaverine/Phentolamine Injectable Vials Due to Sterility Concerns
FDA (Drugs) · 2023-02-01
- SevereVitalab Pharmacy Recalls Sterile Injectable Drug Due to Sterility Concerns
FDA (Drugs) · 2018-05-16
- HighInjectable Papaverine/Phentolamine Recalled Due to Sterility Assurance Failure
FDA (Drugs) · 2022-11-09
- SevereVitalab Pharmacy Recalls Sterile Injectable Drugs Due to Sterility Concerns
FDA (Drugs) · 2018-05-16